The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis [PDF]
Background Since 2015, an infliximab biosimilar, CT-P13, has been approved for commercial use in many countries, easing the economic burden borne by society and patients.
Xinyue Hu +6 more
doaj +2 more sources
Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study [PDF]
Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX to CT‐P13 and ...
Stefano Mazza +21 more
doaj +2 more sources
Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis. [PDF]
Background/Objectives: CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in ...
Uslu S +27 more
europepmc +7 more sources
Background: As the patents of originator biologics are expiring, biosimilar versions are becoming available for the treatment of inflammatory bowel disease (IBD).
Viktoria Bergqvist +11 more
doaj +2 more sources
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study [PDF]
To investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS).This open-label extension study recruited patients with AS who completed a 54-week, randomised controlled study comparing CT-P13 with RP (PLANETAS). CT-P13 (5 mg/kg)
Park, Won +16 more
openaire +5 more sources
Outcomes of an Intravenous to Subcutaneous Infliximab (CT‐P13) Strategy in Takayasu Arteritis: A Proof‐of‐Concept Prospective Study [PDF]
Objectives To evaluate persistence, outcomes, safety, and remission maintenance after switching from intravenous infliximab (IV‐IFX) to subcutaneous infliximab (SC‐IFX, CT‐P13) in patients with Takayasu arteritis (TA). Methods We conducted a prospective,
Luca Iorio +6 more
doaj +2 more sources
Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice [PDF]
Background/Aims An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease.
Tomoo Nakagawa +8 more
doaj +2 more sources
Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report [PDF]
Available data on switching from originator infliximab to CT‐P13 in patients with inflammatory bowel disease are reassuring regarding safety and efficacy outcomes.
Anne S. Strik +2 more
doaj +2 more sources
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases [PDF]
Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy.
Joanna Sieczkowska +4 more
doaj +3 more sources
Efficacy, Pharmacokinetics and Safety of Subcutaneous Versus Intravenous CT-P13 in Rheumatoid Arthritis: A Randomized Phase I/III Trial [PDF]
Pavel Shesternya +2 more
exaly +2 more sources

